Literature DB >> 365209

Plasma protein binding interaction between phenytoin and valproic acid in vitro.

A Monks, S Boobis, J Wadsworth, A Richens.   

Abstract

1 Valproic acid or phenytoin were added to fresh human serum in varying concentrations and their binding characteristics determined by the method of Scatchard (1949). 2 Changes in serum albumin binding were investigated for phenytoin in the presence of 280, 560, 1050 and 2100 mumol l-1 valproic acid, and for valproic acid in the presence of 40, 120, 280 and 480 mumol l-1 phenytoin. 3 Phenytoin appeared to bind to a single site on the albumin molecule and could be competitively displaced from this site by concentrations of valproic acid above 280 mumol l-1. 4 At high concentrations of valproic acid, the affinity of phenytoin for albumin was greatly decreased but the number of available binding sites was increased from one to four. 5 Valproic acid was bound to two high affinity and five low affinity binding sites but the latter were not detectable at valproic acid concentrations below 2100 mumol l-1. 6 Phenytoin displaced valproic acid from its high affinity binding sites, although this was statistically significant only at a concentration of 480 mumol l-1 phenytoin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365209      PMCID: PMC1429699          DOI: 10.1111/j.1365-2125.1978.tb00871.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Drug interaction: diazoxide and diphenylhydantoin.

Authors:  T F Roe; R L Podosin; M E Blaskovics
Journal:  J Pediatr       Date:  1975-09       Impact factor: 4.406

2.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

3.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

4.  Two dimensional immunoelectrophoresis of human serum proteins for the investigation of protein drugs.

Authors:  R L Kramer; A Richens
Journal:  Br J Pharmacol       Date:  1972-05       Impact factor: 8.739

5.  Plasma protein binding of tricyclic anti-depressants in man.

Authors:  O Borgå; D L Azarnoff; G P Forshell; F Sjöqvist
Journal:  Biochem Pharmacol       Date:  1969-09       Impact factor: 5.858

6.  Valproate may lower serum-phenytoin.

Authors:  P N Patsalos; P T Lascelles
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

7.  Serum protein binding of thyroxine and diphenylhydantoin.

Authors:  R W Lightfoot; C L Christian
Journal:  J Clin Endocrinol Metab       Date:  1966-03       Impact factor: 5.958

Review 8.  Interactions with antiepileptic drugs.

Authors:  A Richens
Journal:  Drugs       Date:  1977-04       Impact factor: 9.546

9.  Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.

Authors:  I Odar-Cederlöf; O Borga
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

  9 in total
  23 in total

Review 1.  What is the true clinical significance of plasma protein binding displacement interactions?

Authors:  L N Sansom; A M Evans
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Disposition of anticonvulsants in childhood.

Authors:  J I Morrow; A Richens
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

4.  Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients.

Authors:  G W Mihaly; F J Vajda; J L Miles; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

5.  Serum protein binding of valproic acid and its displacement by palmitic acid in vitro.

Authors:  A Monks; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.

Authors:  F J Rowell; S M Hui; A F Fairbairn; D Eccleston
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Effect of valproate on free plasma phenytoin concentrations.

Authors:  L M Tsanaclis; J Allen; E Perucca; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

10.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.